Stock Research for ACAD

ACAD

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACAD Stock Chart & Research Data

The ACAD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACAD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACAD Due diligence Resources & Stock Charts

The ACAD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACAD Detailed Price Forecast - CNN Money CNN View ACAD Detailed Summary - Google Finance
Yahoo View ACAD Detailed Summary - Yahoo! Finance Zacks View ACAD Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACAD Trends & Analysis - Trade-Ideas Barrons View ACAD Major Holders - Barrons
NASDAQ View ACAD Call Transcripts - NASDAQ Seeking View ACAD Breaking News & Analysis - Seeking Alpha
Spotlight View ACAD Annual Report - CompanySpotlight.com OTC Report View ACAD OTC Short Report - OTCShortReport.com
TradeKing View ACAD Fundamentals - TradeKing Charts View ACAD SEC Filings - Bar Chart
WSJ View Historical Prices for ACAD - The WSJ Morningstar View Performance/Total Return for ACAD - Morningstar
MarketWatch View the Analyst Estimates for ACAD - MarketWatch CNBC View the Earnings History for ACAD - CNBC
StockMarketWatch View the ACAD Earnings - StockMarketWatch MacroAxis View ACAD Buy or Sell Recommendations - MacroAxis
Bullish View the ACAD Bullish Patterns - American Bulls Short Pains View ACAD Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACAD Stock Mentions - StockTwits PennyStocks View ACAD Stock Mentions - PennyStockTweets
Twitter View ACAD Stock Mentions - Twitter Invest Hub View ACAD Investment Forum News - Investor Hub
Yahoo View ACAD Stock Mentions - Yahoo! Message Board Seeking Alpha View ACAD Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACAD - SECform4.com Insider Cow View Insider Transactions for ACAD - Insider Cow
CNBC View ACAD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACAD - OTC Markets
Yahoo View Insider Transactions for ACAD - Yahoo! Finance NASDAQ View Institutional Holdings for ACAD - NASDAQ


Stock Charts

FinViz View ACAD Stock Insight & Charts - FinViz.com StockCharts View ACAD Investment Charts - StockCharts.com
BarChart View ACAD Stock Overview & Charts - BarChart Trading View View ACAD User Generated Charts - Trading View




Latest Financial News for ACAD


Glancy Prongay & Murray LLP Announces Investigation On Behalf Of ACADIA Pharmaceuticals Inc. Investors (ACAD)
Posted on Friday January 11, 2019

Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (“ACADIA” or “the Company”) and whether the Company’s officers and directors complied with their legal obligations to the Company and its shareholders. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [NUPLAZID] had been approved too quickly, based on too little evidence that it was safe or effective. GPM’s investigation focuses on whether the Company and its directors breached any fiduciary duties owed to shareholders.


Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and ACADIA Pharmaceuticals
Posted on Thursday January 10, 2019

NEW YORK, NY / ACCESSWIRE / January 10, 2019 / U.S. markets rose for the fourth consecutive session on Wednesday as minutes released from the Federal Reserve's meeting in December showed the Fed would ...


See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
Posted on Wednesday January 09, 2019

# ACADIA Pharmaceuticals Inc ### NASDAQ/NGS:ACAD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderately high for ACAD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding ACAD is favorable, with net inflows of $8.83 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.


Here's Why ACADIA Pharmaceuticals Dropped 15.2% in December
Posted on Tuesday January 08, 2019

The pharma company was an easy target for Mr. Market during last month's sell-off, but it appears well positioned for a rebound in 2019.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.